M Dowsett

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer
    M Dowsett
    Department of Academic Biochemistry, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 6:2260-7. 2000
  2. ncbi Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 86:255-63. 2003
  3. ncbi Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden NHS Trust, London, UK
    J Pathol 199:418-23. 2003
  4. ncbi Preoperative models to evaluate endocrine strategies for breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Clin Cancer Res 9:502S-10S. 2003
  5. ncbi Breast cancer: aromatase inhibitors take on tamoxifen
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden NHS Trust, Fulham Road, London, UK
    Nat Med 8:1341-4. 2002
  6. ncbi Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    Cytometry 32:291-300. 1998
  7. ncbi Theoretical considerations for the ideal aromatase inhibitor
    M Dowsett
    Royal Marsden Hospital, London, UK
    Breast Cancer Res Treat 49:S39-44; discussion S73-7. 1998
  8. ncbi Efforts to link biological and clinical breast cancer research
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Breast 12:442-6. 2003
  9. ncbi HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer
    M Dowsett
    Breast Unit, Royal Marsden Hospital, London, United Kingdom
    Cancer Res 61:8452-8. 2001
  10. ncbi Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer
    M Dowsett
    Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    Endocr Relat Cancer 8:191-5. 2001

Collaborators

Detail Information

Publications127 found, 100 shown here

  1. ncbi Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer
    M Dowsett
    Department of Academic Biochemistry, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 6:2260-7. 2000
    ..05 < P < 0.10). Idoxifene was well tolerated in all patients. Idoxifene has an antiproliferative effect in ER-positive but not ER-negative breast cancers, and no significant effect on apoptosis in the short-term...
  2. ncbi Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 86:255-63. 2003
    ..This provides a possible explanation why the clinical efficacy of tamoxifen combined with an aromatase inhibitor appears to be equivalent to that of tamoxifen alone...
  3. ncbi Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden NHS Trust, London, UK
    J Pathol 199:418-23. 2003
    ..These data support an algorithm in which FISH testing is restricted to IHC 2+ tumours in reference centres. The results may not extrapolate to laboratories with less experience or using different methodologies...
  4. ncbi Preoperative models to evaluate endocrine strategies for breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Clin Cancer Res 9:502S-10S. 2003
    ..It is possible to evaluate potential resistance mechanisms by associating changes in Ki67 or apoptosis with the expression of the putative determinant of resistance in the short-term presurgical model...
  5. ncbi Breast cancer: aromatase inhibitors take on tamoxifen
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden NHS Trust, Fulham Road, London, UK
    Nat Med 8:1341-4. 2002
  6. ncbi Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    Cytometry 32:291-300. 1998
    ..3-11.3% by flow cytometry) and between different phases of treatment, and should provide a useful tool for further research on this process in solid tumours...
  7. ncbi Theoretical considerations for the ideal aromatase inhibitor
    M Dowsett
    Royal Marsden Hospital, London, UK
    Breast Cancer Res Treat 49:S39-44; discussion S73-7. 1998
    ..The possibility is considered that the apparent small differences between the triazoles may be associated with differences in clinical effectiveness. These new compounds merit consideration for studies of breast cancer prevention...
  8. ncbi Efforts to link biological and clinical breast cancer research
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Breast 12:442-6. 2003
    ..Biomarker analyses have reduced statistical power compared with whole trials. Neoadjuvant therapy is an advantageous scenario to link biological and clinical research...
  9. ncbi HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer
    M Dowsett
    Breast Unit, Royal Marsden Hospital, London, United Kingdom
    Cancer Res 61:8452-8. 2001
    ..This together with high baseline proliferation is likely to translate to poor clinical response...
  10. ncbi Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer
    M Dowsett
    Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    Endocr Relat Cancer 8:191-5. 2001
    ..It is concluded that incomplete hormonal resistance results from co-expression of HER-2 and ER and that this may differ between different hormonal agents...
  11. ncbi Assessment of HER2 status in breast cancer: why, when and how?
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Eur J Cancer 36:170-6. 2000
    ....
  12. ncbi Use of risk determinants for different breast cancer prevention strategies
    M Dowsett
    Academic Department of Biochemistry, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK
    Eur J Cancer 36:1283-7. 2000
    ..This article seeks to integrate the information from several sources and concludes that the prophylactic strategies should differ according to different risk profiles...
  13. ncbi Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women
    M Dowsett
    Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
    Cancer Chemother Pharmacol 46:35-9. 2000
    ..Hence, the effects of the nonsteroidal aromatase inhibitor anastrozole on serum oestrogen concentrations were compared in 24 healthy postmenopausal Japanese women and 24 healthy postmenopausal Caucasian women...
  14. ncbi Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer
    Giles Davies
    Academic Departments of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Clin Cancer Res 9:2651-6. 2003
    ....
  15. ncbi New biology of the oestrogen receptor
    Mitch Dowsett
    Biochemistry Department, Royal Marsden Hospital, SW3 6JJ, London, UK
    Lancet 362:260-2. 2003
  16. ncbi New hurdles for translational research
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Breast Cancer Res 2:241-3. 2000
    ..This is particularly significant when emerging technologies are expected to elicit major advances in clinical cancer research...
  17. ncbi Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
    M Dowsett
    Academic Department of Biochemistry, The Royal Marsden NHS Trust, London, UK
    Ann Oncol 17:818-26. 2006
    ..The measurement of tumour biomarkers should allow better selection of patients for such treatment or for therapies such as aromatase inhibitors...
  18. ncbi Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer
    J Chang
    Departments of Medicine and Computing, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    J Clin Oncol 17:3058-63. 1999
    ..To determine whether pretreatment clinical features and molecular markers, together with changes in these factors, can predict treatment response and survival in patients with primary operable breast cancer who receive neoadjuvant therapy...
  19. ncbi EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
    A H Evans
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, UK
    Br J Cancer 102:1235-43. 2010
    ..We investigated whether AEE788 (a combined inhibitor of EGFR, HER2 and VEGFR) plus tamoxifen or letrozole enhanced the individual anti-tumour effects of these agents...
  20. ncbi Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis
    S R Johnston
    Department of Medicine, The Royal Marsden NHS Trust, London, England
    Cancer Res 59:3646-51. 1999
    ..Sustained induction of apoptosis may contribute to prolonged antagonism of E2-dependent growth, and it occurred to a greater extent following 3 months of idoxifene, compared to tamoxifen...
  21. ncbi Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Br J Cancer 64:887-94. 1991
    ..d., two at 800 mg b.d., and one at 1200 mg b.d. The most frequent side-effects were nausea and lethargy. One patient showed an objective response to treatment...
  22. ncbi Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
    A Makris
    Royal Marsden Hospital, Sutton, Surrey, UK
    Breast Cancer Res Treat 48:11-20. 1998
    ..To determine the effects of tamoxifen on the levels of hormone receptors and proliferation markers in the early phase of treatment and the relationship of the changes with tumor response in patients with primary breast cancer...
  23. ncbi Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma
    J Chang
    Department of Biochemistry, Medicine and Computing, The Royal Marden Hospital, Sutton, Surrey, United Kingdom
    Cancer 89:2145-52. 2000
    ..The objective of this clinical study was to examine in vivo changes in apoptotic index (AI), Bcl-2 expression, proliferation (Ki-67 and S-phase fraction [SPF]), and ploidy as potential indicators of chemoresponsiveness...
  24. ncbi Aromatase inhibitors and male breast cancer
    E Arriola
    Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London, UK
    Clin Transl Oncol 9:192-4. 2007
    ..Here we report a case of a male patient with metastatic breast cancer treated with letrozole who achieved clinical response associated with a decrease in blood oestradiol levels...
  25. ncbi Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas
    P A Ellis
    Academic Department of Biochemistry, Royal Marsden NHS Trust, Sutton, UK
    Br J Cancer 73:640-3. 1996
    ..This can be done using simple, widely available technology and provides the opportunity to perform large-scale retrospective analyses of archival materials...
  26. ncbi Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    Endocr Relat Cancer 12:S113-7. 2005
    ..There is an unfortunate paucity of clinical and biological data on acquired resistance to aromatase inhibitors...
  27. ncbi Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen
    I N Fernando
    Department of Radiotherapy and Oncology, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 70:1211-6. 1994
    ..We conclude that changes in ploidy and SPF detected by flow cytometry may predict initial response and the likelihood of relapse of breast tumours to tamoxifen before clinical changes become evident. These data justify a larger study...
  28. ncbi The pharmacology of letrozole
    B P Haynes
    Department of Academic Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 87:35-45. 2003
    ..A consistent effect of letrozole on serum lipids has not been demonstrated...
  29. ncbi Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer
    C D Archer
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 89:1035-41. 2003
    ..Pretreatment proliferation and GI are however predictive of response to chemotherapy in breast cancer...
  30. ncbi The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling
    L A Martin
    Academic Department of Biochemistry, Institute of Cancer Research, London, UK
    Endocr Relat Cancer 12:1017-36. 2005
    ..These results support the use of ICI in women with ER-positive breast cancer who have relapsed on an aromatase inhibitor...
  31. ncbi Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial
    M Dowsett
    CRC and UCL Cancer Trials Centre, University College London, Stephenson House, 158 160 N Gower Street, London, NW1 2ND, UK
    Br J Cancer 85:317-24. 2001
    ....
  32. ncbi Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial
    S Banerjee
    Breast Unit, Royal Marsden Hospital, London and Sutton, London, UK
    Ann Oncol 16:1632-8. 2005
    ..CONCLUSION: Anastrozole did not have a detrimental effect on lipid profiles following 3 months of therapy. There was a significant increase in CTx with anastrozole in contrast to tamoxifen...
  33. ncbi Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer
    J H Davies
    Department of Urology, St Georges Hospital, Tooting, London, UK
    Br J Cancer 66:139-42. 1992
    ..Further investigation of the effects of aromatase inhibitors on prostatic biology, and bone metabolism in patients with metastatic prostate cancer, would appear worthwhile...
  34. ncbi Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression
    F A MacNeill
    Section of Medicine, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 69:1171-5. 1994
    ..2 +/- 9.1%, P < 0.025). This effect on Oe1S may be due to an influence of AG on oestrogen metabolism...
  35. ncbi A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen
    S R D Johnston
    Cancer Research UK, Lincoln's Inn Fields, London, WC2A 3PX, UK
    Cancer Chemother Pharmacol 53:341-8. 2004
    ....
  36. ncbi Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer
    H Anderson
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Ann Oncol 22:1770-6. 2011
    ..Here, we aim to determine the effectiveness of AIs in that setting according to quantitative levels of estrogen receptor (ER), progesterone receptor (PgR) and Ki67 or human epithelial growth factor receptor-2 (HER-2) status...
  37. ncbi The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Br J Cancer 79:311-5. 1999
    ..In addition, the oestradiol suppressant effects of anastrozole appear unaffected by tamoxifen...
  38. ncbi Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Breast Cancer Res Treat 56:25-34. 1999
    ..Existing clinical-pharmacological correlates suggest that these increases in pharmacological effectiveness may result in enhanced clinical effectiveness...
  39. ncbi A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients
    M Dowsett
    Department of Biochemical Endocrinology, Royal Marsden Hospital, London, UK
    Br J Cancer 62:834-7. 1990
    ..We conclude that the slow release formulation of leuprorelin is effective in breast cancer treatment and that there is no major detriment to the use of the 3.75 rather than 7.5 mg dose...
  40. ncbi The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer
    R C Stein
    Clinical Oncology Unit, St George s Hospital Medical School, London, UK
    Br J Cancer 62:679-83. 1990
    ..The combination of LHRH analogue and aromatase inhibitor may prove to be a superior treatment to LHRH analogue alone in these patients...
  41. ncbi The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance
    S R Johnston
    Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
    Br J Cancer 75:804-9. 1997
    ..The drug's reduced agonist activity may, in part, explain these observations and indicate a preferable biochemical profile for breast cancer treatment...
  42. ncbi Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer
    P N Mainwaring
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    J Clin Pathol 51:34-7. 1998
    ..The use of biotinylated nucleotides to identify DNA strand breaks is a commonly reported method of estimating cells numbers undergoing apoptosis; however, investigators report inconsistent results for a variety of reasons...
  43. ncbi An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition
    L A Martin
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW36JB, UK
    Steroids 76:772-6. 2011
    ..Furthermore analysis of temporal changes in gene expression during the acquisition of resistance highlight growth factor receptor pathways as key mediators of this adaptive process...
  44. ncbi Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer
    L Assersohn
    Breast Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    Breast Cancer Res Treat 82:113-23. 2003
    ..CONCLUSION: Ki67 is unlikely to be useful as a predictive marker in individual patients. Further molecular markers that predict lack of response continue to be required...
  45. ncbi Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)
    M Arnedos
    Department of Medicine, Breast Unit, The Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Ann Oncol 20:1948-52. 2009
    ....
  46. ncbi Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer
    H R Bonnefoi
    Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Br J Cancer 73:539-42. 1996
    ..No serious adverse events were reported. In conclusion, fadrozole is a clinically active aromatase inhibitor with a low incidence of side-effects and phase III clinical trials in post-menopausal women are currently under way...
  47. ncbi Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer
    J C Newby
    Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
    Br J Cancer 71:1237-42. 1995
    ..02) and overall survival (P = 0.03) when measured by this immunohistochemical assay, but was not significant when measured by ligand-binding assay...
  48. ncbi Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance
    I Plaza-Menacho
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Oncogene 29:4648-57. 2010
    ..Together these findings identify RET as a potentially important therapeutic target in ERalpha-positive breast cancers and in particular in tamoxifen-resistant tumors...
  49. ncbi High incidence of HER-2 positivity in inflammatory breast cancer
    M Parton
    Breast Unit, Royal Marsden Hospital Trust and Institute of Cancer Research, Fulham Rd, London SW3 6JJ, UK
    Breast 13:97-103. 2004
    ..Early HER-2 directed therapy (such as the monoclonal antibody trastuzumab) as a part of multimodal treatment may improve outcome in this poor prognosis cancer...
  50. ncbi Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment
    S C Drury
    Translational Research, The Breakthrough Breast Cancer Research Centre, London, UK
    Endocr Relat Cancer 18:565-77. 2011
    ..There is no evidence for IGF1R gain in tamoxifen resistance; increases in stathmin levels suggest that activation of the PI3K pathway may have contributed, but PTEN loss and PIK3CA hotspot mutations were relatively rare...
  51. ncbi Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
    A Leary
    Academic Department of Biochemistry, Royal Marsden Hospital Institute of Cancer Research, London, UK
    Br J Cancer 95:661-6. 2006
    ..In time, breast cancer treatment will become truly individualised because physicians will be able to match patients with a variety of disease phenotypes to optimal combination therapies...
  52. ncbi Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors
    I M Boeddinghaus
    The Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK
    J Steroid Biochem Mol Biol 79:85-91. 2001
    ..Neither anastrozole nor letrozole have any effect on plasma concentrations of tamoxifen when given in combination with it...
  53. ncbi Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
    T Powles
    Royal Marsden NHS Trust, London and Sutton, Surrey, UK
    Lancet 352:98-101. 1998
    ..We have undertaken a trial of tamoxifen in healthy women who are at increased risk of breast cancer because of family history. We report a planned interim analysis...
  54. ncbi Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
    S Barton
    Department of Medicine, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 106:1760-5. 2012
    ..We assessed its utility in personalising breast cancer treatment in a clinical practice setting, through comparison with Adjuvant! Online (AoL) and the Nottingham Prognostic Index (NPI)...
  55. ncbi Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors
    A Kendall
    Academic Department of Biochemistry, Royal Marsden Foundation NHS Trust, London, UK
    Ann Oncol 17:584-7. 2006
    ..This reverses the estradiol suppression achieved by aromatase inhibitors in women with breast cancer and is contraindicated...
  56. ncbi Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer
    S J Stanway
    Imperial College London, London, UK
    Anticancer Res 31:1367-72. 2011
    ..In contrast, little is known about the effects of aromatase inhibitors or anti-estrogens on STS activity or serum androgen levels...
  57. ncbi Aromatase inhibition in advanced prostatic cancer: preliminary communication
    R J Shearer
    Department of Urology, St Georges Hospital, Tooting, London, UK
    Br J Cancer 62:275-6. 1990
    ..The mechanism of action of 4-OHA in palliating patients with advanced prostatic cancer is obscure at present, but may represent an important new treatment modality which may lead to greater insight into prostatic biology...
  58. ncbi Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects
    I L Crighton
    Department of Medicine, Royal Marsden Hospital, London, UK
    Br J Cancer 60:644-8. 1989
    ....
  59. ncbi Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells
    V M Macaulay
    Chester Beatty Laboratories, Institute of Cancer Research, London, UK
    Br J Cancer 69:77-83. 1994
    ..1 cells were completely reversible by aromatase inhibitor CGS 16949A. The Arom. 1 cell line may contribute to the development of an in vivo model of intratumoral aromatase, to study the biological significance of this phenomenon...
  60. ncbi Oestradiol synthesis from oestrone in malignant breast epithelial cells: studies on a high affinity, 80 kDa form of oestradiol dehydrogenase
    C J Newton
    Department of Academic Biochemistry, Royal Marsden Hospital, London, England
    J Steroid Biochem Mol Biol 42:891-900. 1992
    ....
  61. ncbi Endocrine treatment of advanced breast cancer
    M Dowsett
    Royal Marsden Hospital, London, England
    Acta Oncol 35:68-72. 1996
    ..In most cases, the clinical effectiveness of these agents remains to be fully established and their optimal therapeutic application is yet to be determined...
  62. ncbi The biology of neoadjuvant chemotherapy for breast cancer
    S Cleator
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Endocr Relat Cancer 9:183-95. 2002
    ..Continuing work using cDNA microarrays may yield new, more reliable indices of likely response and an improved insight into biological processes related to chemotherapeutic response...
  63. ncbi Recent advances in the clinical application of aromatase inhibitors
    C Harper-Wynne
    Academic Department of Biochemistry, The Royal Marsden Hospital, Fulham Road, SW3 3JJ, London, UK
    J Steroid Biochem Mol Biol 76:179-86. 2001
    ..On-going clinical trials in the adjuvant setting and prospective prevention studies will elucidate whether these drugs have a yet greater role in breast cancer...
  64. ncbi Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients
    M Dowsett
    Royal Marsden NHS Trust, London, England SM2 5PT
    Cancer Epidemiol Biomarkers Prev 10:961-6. 2001
    ..This provides support for raloxifene having a breast cancer preventive effect in postmenopausal women...
  65. ncbi The influence of CGS 16949A on peripheral aromatisation in breast cancer patients
    P E Lønning
    Department of Medicine, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 63:789-93. 1991
    ..d. seems to result in greater than 90% aromatase inhibition. These data are consistent with previous observations that the higher dose is more effective in suppression of plasma oestradiol levels...
  66. ncbi Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques
    A E Ring
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 92:906-12. 2005
    ..001) or IMS (83 vs 48%, P<0.001).The use of a multimarker real-time RT-PCR assay was therefore found to be the most sensitive technique for the detection of circulating epithelial cells in the blood of patients with breast cancer...
  67. ncbi Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention
    G Davies
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Ann Oncol 13:669-78. 2002
    ..Their potential role in chemoprevention of mammary carcinogenesis in rats has already been investigated. What remains to be seen is if these findings can be extrapolated to human studies...
  68. ncbi Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance
    S R Johnston
    Department of Medicine, Royal Marsden Hospital and Institute of Cancer Research, London, England
    Clin Cancer Res 5:251-6. 1999
    ..These observations support the need for further evaluation of these markers in breast tumors as predictors of TAM resistance...
  69. ncbi Clinical pharmacology of selective estrogen receptor modulators
    B Haynes
    Department of Academic Biochemistry, Royal Marsden Hospital, London, England
    Drugs Aging 14:323-36. 1999
    ..These compounds promise a new era of disease prevention in the aging woman and their therapeutic potential is currently being evaluated in large-scale clinical trials...
  70. ncbi Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer
    L R Kelland
    CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Surrey SM2 5NG, United Kingdom
    Clin Cancer Res 7:3544-50. 2001
    ....
  71. ncbi A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer
    T J Powles
    Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 60:126-31. 1989
    ..At this stage no untoward long-term risks have been identified, and it is therefore proposed that a large multicentre trial should be started...
  72. ncbi The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients
    M Dowsett
    Department of Biochemical Endocrinology, Chelsea Hospital for Women, London, UK
    Br J Cancer 57:190-2. 1988
    ....
  73. ncbi Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy
    J Y Pierga
    Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
    Br J Cancer 96:341-51. 2007
    ..2-11p15.5. The modest chemotherapy-driven genomic changes, despite profound loss of cell numbers, suggest that there is little therapeutic selection of resistant non-modal cell lineages...
  74. ncbi Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
    David S P Tan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res Treat 111:27-44. 2008
    ....
  75. ncbi Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy
    John M S Bartlett
    Endocrine Cancer Research Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom
    J Clin Oncol 25:4423-30. 2007
    ..We tested interactions between ER and HER-2 to determine if they may modulate breast cancer nodal metastasis and proliferation...
  76. ncbi The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo
    Lesley Ann Martin
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, Fulham Road, London, SW3 6JB United Kingdom
    Mol Cancer Ther 6:2458-67. 2007
    ..Enhanced G1 arrest due to modulation of cell cycle regulatory proteins may be the underlying mechanism for the positive interaction between FTIs and tamoxifen...
  77. ncbi Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)
    Ander Urruticoechea
    Institut Catala d Oncologia, Hospital Duran i Reynalds, Gran Via km 2 7 L Hospitalet de Llobregat, Barcelona, Spain
    Breast Cancer Res Treat 110:411-6. 2008
    ..We report an audit of our experience with the luteinising hormone-releasing hormone agonist, goserelin, to achieve transient ovarian suppression during chemotherapy as a means of preserving ovarian function...
  78. ncbi Mechanisms of disease: angiogenesis and the management of breast cancer
    Susana Banerjee
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, UK
    Nat Clin Pract Oncol 4:536-50. 2007
    ..In addition, we describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimum use of these agents for the treatment of breast cancer...
  79. ncbi A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer
    Ian E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 25:3816-22. 2007
    ..We have therefore investigated whether neoadjuvant gefitinib, an EGFR inhibitor, might overcome biologic and clinical resistance to neoadjuvant anastrozole in a phase II placebo-controlled trial...
  80. ncbi Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer
    Ander Urruticoechea
    Translational Research Laboratory, Institut Catala d Oncologia, IDIBELL, Gran Via s n, Km 2 7, L Hospitalet de Llobregat, Barcelona, 08907, Spain
    Breast Cancer Res Treat 109:463-70. 2008
    ..Expression of the following genes at both time points was determined: Ki-67, Cyclin D1, pS2, Trefoil Factor 3, PDZ domain containing 1, Ubiquitin-conjugating enzyme E2C, Stanniocalcin 2, Topoisomerase 2 alfa, MAN1A1 and FAS...
  81. ncbi Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial
    Ernst Kubista
    Division of Special Gynecology, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 13:4185-90. 2007
    ..5 mg tibolone on breast cancer in postmenopausal women, in particular on tissue proliferation (STEM, Study of Tibolone Effects on Mamma carcinoma tissue)...
  82. ncbi Molecular response to aromatase inhibitor treatment in primary breast cancer
    Alan Mackay
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res 9:R37. 2007
    ..Little is known of the molecular effects of these agents on human breast carcinomas in vivo...
  83. ncbi Aromatase inhibitors in breast cancer
    Ian E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
    N Engl J Med 348:2431-42. 2003
  84. ncbi Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels
    Jurgen Geisler
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Steroid Biochem Mol Biol 104:27-34. 2007
    ..These findings suggest that leptin may influence on aromatase activity in vivo, providing a possible link between body weight and plasma estrogen levels as well as breast cancer risk...
  85. ncbi HER2 testing in the UK: consensus from a national consultation
    Mitch Dowsett
    The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    J Clin Pathol 60:685-9. 2007
    ..To gain an understanding of current attitudes among oncologists and pathologists to prospective HER2 testing in breast cancer and to gauge whether a national consensus exists regarding extent and quality of testing...
  86. ncbi Current status of HER2 testing
    Angelo Di Leo
    Translationsl Research Unit, Department of Chemotherapy, Institut Jules Bordet, Rue Heger Bordet 1, B 1000 Brussels, Belgium
    Oncology 63:25-32. 2002
    ....
  87. ncbi Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines
    Edurne Arriola
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Lab Invest 88:491-503. 2008
    ..The 17q12 amplicon is complex and harbours multiple genes that may be associated with breast cancer development and progression, and potentially exploitable as therapeutic targets...
  88. ncbi Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
    Jurgen Geisler
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Clin Oncol 20:751-7. 2002
    ..To compare the effects of the two novel, potent, nonsteroidal aromatase inhibitors anastrozole and letrozole on total-body aromatization and plasma estrogen levels...
  89. ncbi Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer
    Christos Sotiriou
    Division of Clinical Sciences, Advanced Technology Center, National Cancer Institute, National Institutes of Health, Gaithersburg, USA
    Breast Cancer Res 4:R3. 2002
    ..Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and to identify those expression profiles that correlate with treatment response...
  90. ncbi Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention
    Catherine Harper-Wynne
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Cancer Epidemiol Biomarkers Prev 11:614-21. 2002
    ..We conclude that any prophylactic effect of letrozole is not likely to be dependent on antiproliferative effects on normal breast. Studies in healthy patients will need to recognize the potential for enhanced bone resorption...
  91. ncbi Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation
    Christina M W Chan
    Department of Academic Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 81:333-41. 2002
    ..Thus, the resistance of these human breast cancer cells to oestrogen-deprivation appears to be due to acquired hypersensitivity which may be explained in part by increased levels of and phosphorylated ERalpha...
  92. ncbi Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications
    Alistair Ring
    Department of Academic Biochemistry, Wallace Wing, Royal Marsden Hospital, London, United Kingdom
    Clin Breast Cancer 4:S34-41. 2003
    ..In contrast, early data from the neoadjuvant setting suggest that responses to aromatase inhibitors may be maintained in patients with HER2 overexpression...
  93. ncbi Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
    Matthew J Ellis
    Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63119, USA
    J Natl Cancer Inst 100:1380-8. 2008
    ....
  94. ncbi ESR1 gene amplification in breast cancer: a common phenomenon?
    Jorge S Reis-Filho
    Nat Genet 40:809-10; author reply 810-2. 2008
  95. ncbi Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer
    Heidi Fiegl
    Department of Gynecological Oncology, UCL Institute for Women s Health, University College London, London, United Kingdom
    Clin Cancer Res 14:3494-502. 2008
    ..The aim of this proof-of-principle study was to assess whether NEUROD1 DNA methylation is able to predict the response to neoadjuvant and adjuvant chemotherapy...
  96. ncbi The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer
    Susana Banerjee
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 14:2656-63. 2008
    ..We investigated the effects of anastrozole and tamoxifen over time on serum VEGF and sVEGFR-1...
  97. ncbi Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo
    Anne Kendall
    Department of Medical Oncology, Guys and St Thomas NHS Foundation Trust, London, UK
    Cancer Epidemiol Biomarkers Prev 17:855-63. 2008
    ..The modest degree of gene change suggests that intermediate markers of chemoprevention may be difficult to identify...
  98. ncbi Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer
    J Michael Dixon
    Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
    J Clin Oncol 26:1671-6. 2008
    ..To compare the effects of anastrozole and letrozole on plasma estradiol (E2) and estrone sulfate (E1S) levels...
  99. ncbi Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial
    Trevor J Powles
    Parkside Oncology Clinic, 49 Parkside, Wimbledon, London SW19 5NB, UK
    J Natl Cancer Inst 99:283-90. 2007
    ..We report the blinded 20-year follow-up (median follow-up = 13 years) of the Royal Marsden trial to identify any long-term prevention of breast cancer associated with tamoxifen treatment...
  100. ncbi Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
    Edurne Arriola
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Breast Cancer Res Treat 106:181-9. 2007
    ....
  101. ncbi Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1)
    Mary S Beattie
    Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, CA, USA
    J Natl Cancer Inst 98:110-5. 2006
    ..The purpose of this study was to determine whether sex hormone levels were associated with breast cancer risk and with response to tamoxifen in a high-risk population...